Intellia Therapeutics News Releases http://ir.intelliatx.com/ Intellia Therapeutics News Releases en Intellia Therapeutics to Participate at June Healthcare Investor Conferences http://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-participate-june-healthcare-investor CAMBRIDGE, Mass. , May 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will participate in the following upcoming healthcare conferences in Thu, 30 May 2019 16:30:00 -0400 Intellia Therapeutics News Releases 8251 Intellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer http://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-names-laura-sepp-lorenzino-phd-chief CAMBRIDGE, Mass. , May 28, 2019 (GLOBE NEWSWIRE) --   Intellia Therapeutics, Inc. , (NASDAQ:NTLA) has named Laura Sepp-Lorenzino , Ph.D., as its new executive vice president and chief scientific officer. Dr. Sepp-Lorenzino brings decades of leadership and research and development experience, and Tue, 28 May 2019 07:50:00 -0400 Intellia Therapeutics News Releases 8231 Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update http://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-quarter-2019-financial Remains on track to submit investigational new drug application in 2020 for its first systemically delivered CRISPR/Cas9-based therapy, NTLA-2001, for treatment of transthyretin amyloidosis Expects to nominate first engineered cell therapy development candidate for treatment of acute myeloid Thu, 02 May 2019 07:30:00 -0400 Intellia Therapeutics News Releases 8166 Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy http://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-presents-new-vivo-and-engineered-cell Intellia scientists advance CRISPR-mediated targeted gene insertion in non-human primates Achieved normal circulating human Factor IX protein levels in non-human primates using targeted gene insertion High rate and specificity of acute myeloid leukemia cell killing progressed using genome-edited, Mon, 29 Apr 2019 07:30:00 -0400 Intellia Therapeutics News Releases 8156 Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company Update http://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-hold-conference-call-discuss-first-quarter CAMBRIDGE, Mass. , April 25, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present first quarter 2019 results and operational highlights in Thu, 25 Apr 2019 07:30:00 -0400 Intellia Therapeutics News Releases 8151 Intellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy http://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-three-oral-presentations-vivo CAMBRIDGE, Mass. , April 15, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced three oral presentations at the 22 nd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place April 29-May 2, 2019 , in Washington, D.C. Mon, 15 Apr 2019 16:30:00 -0400 Intellia Therapeutics News Releases 8121 Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results http://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fourth-quarter-and-full-year-1 Confirmed improved non-human primate liver editing and protein reduction of greater than 95 percent in transthyretin amyloidosis program; investigational new drug application on track for 2020 submission Engineered cell therapy platform will enable wholly owned development candidate for acute Wed, 27 Feb 2019 06:30:00 -0500 Intellia Therapeutics News Releases 8056 Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors http://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-names-fred-cohen-md-board-directors CAMBRIDGE, Mass. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has appointed Fred Cohen , M.D., D.Phil, F.A.C.P., to its board of Thu, 24 Jan 2019 07:00:00 -0500 Intellia Therapeutics News Releases 7981 Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population http://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-and-novartis-expand-cell-therapy – Intellia’s Right to Use Proprietary Lipid Nanoparticle Technology Extended to All Settings – Intellia Will Receive a One-time $10 Million Payment CAMBRIDGE, Mass. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing Thu, 06 Dec 2018 07:30:00 -0500 Intellia Therapeutics News Releases 7931 Intellia Therapeutics to Present at November Healthcare Investor Conferences http://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-present-november-healthcare-investor-0 CAMBRIDGE, Mass. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will participate in the following upcoming healthcare conferences in Thu, 08 Nov 2018 16:30:00 -0500 Intellia Therapeutics News Releases 7921